Safety and Performance of the Novalung Ultimate Kit and Xenios 2.0 During Stationary Use in Hospital and Ground-based Transport of Patients on Extracorporeal Life Support (ECLS)

Not yet recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

April 30, 2027

Conditions
Cardio-Respiratory FailureExtracorporeal Membrane Oxygenation ComplicationAcute Lung Injury
Interventions
DEVICE

Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG)

Patients will receive ECLS treatment using the Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG) during ground-based inter-hospital patient transport and/ or stationary treatment according to their intended use and local standards/ requirements.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alcedis GmbH

INDUSTRY

lead

Xenios AG

INDUSTRY

NCT07156669 - Safety and Performance of the Novalung Ultimate Kit and Xenios 2.0 During Stationary Use in Hospital and Ground-based Transport of Patients on Extracorporeal Life Support (ECLS) | Biotech Hunter | Biotech Hunter